Aralez launches YOSPRALA in U.S.

Aralez Pharmaceuticals' YOSPRALA -- a once-a-day medication that combines aspirin, an anti-platelet agent and omeprazole into a proton pump inhibitor (PPI) -- is now available in the United States.

It was developed to treat patients who must take aspirin as a secondary means of prevention for cardiovascular (CV) events.

"We are pleased to announce the commercial launch of YOSPRALA in the U.S. supported by our fully trained, 110 person sales force deployed to promote YOSPRALA to cardiologists and high prescribing primary care physicians," Aralez CEO Adrian Adams said. "YOSPRALA, a product that is specifically designed to reduce aspirin intolerance and therefore potentially improve compliance to therapy, has the promise to benefit healthcare practitioners, payers and patients. We believe that YOSPRALA represents a significant market opportunity and will contribute to solidifying our core therapeutic anchor position in cardiovascular disease alongside Fibricor."

YOSPRALA uses the Intelli-COAT system to support patients who have a risk of cardio and gastro events. The Intelli-COAT system is designed to administer a 40 mg dose of immediate-release omeprazole prior to a delayed-release 81 mg or 325 mg dose of enteric-coated aspirin core.